drugset / Trial / NCT05182658
Empagliflozin in Hypertrophic Cardiomyopathy
Phase 3
Active not recruiting
250 enrolled
National Institute of Cardiology, Warsaw, Poland
Amsterdam UMC, location VUmc · collabMedical University of Bialystok · collabUniversity of Eastern Finland · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group. The primary endpoint of the study will be the change in peak oxygen uptake (VO2 max) measured in a cardiopulmonary exercise test. VO2max is an objective indicator of physical performance and will be evaluated before and after empagliflozin or placebo treatment.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2026-09-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Empagliflozin | Small molecule | 10 mg | — |